|
|
Medscape Education
The Atopic Dermatitis Learning Center: Riding the Next Wave
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 5% to 30% of children and 1% to 10% of adults globally. It is characterized by recurrent eczematous lesions and intense itch and can have a severe impact on quality of life. Numerous agents that target the immunological mechanism of AD are under investigation in pediatric and adult patients. It is imperative that clinicians have the most recent data to provide optimal outcomes for their patients with AD.
|
|
IEC Statement on New COVID 19 Vaccines
IEC has issued a position statement on COVID 19 Vaccines and Atopic Dermatitis to address concerns about potential risks associated with these novel vaccinations.
|
Read the latest IEC articles, published in JAAD International, British Journal of Dermatology and The Journal of Allergy and Clinical Immunology.
Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council Eichenfield L, Kusari A, Han A, Marcoux D, Nosbaum A, Stalder JF, Barbarot S, Deleuran, M, Lio P (2021). JAAD International. https://doi.org/10.1016/j.jdin.2021.01.001
Priority research questions in atopic dermatitis: An International Eczema Council eDelphi consensus. Abuabara K, Nicholls S., Langan S, Guttman‐Yassky E, Reynolds N, Paller A, Brown S (2021). British Journal of Dermatology. Accepted Author Manuscript. https://doi.org/10.1111/bjd.19874
Biomarkers in atopic dermatitis - a review on behalf of the International Eczema Council. Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, Guttman-Yassky E. [published online ahead of print, 2021 Jan 28]. The Journal of Allergy and Clinical Immunology. 2021;S0091-6749(21)00096-8. doi:10.1016/j.jaci.2021.01.013
For all IEC publications, see our expanded list.
|
IEC Webcasts Available
Webcasts of IEC symposia on "Biomarkers" are now available on-demand.
|
NEA Presents Eczema Expo 2020
The National Eczema Association will be holding its Eczema Expo 2020 virtually this year.
For further details, see https://nationaleczema.org/eczema-expo/ |
Coronavirus SECURE-AD Registry
SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis; www.covidderm.org) is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in AD patients who have been Covid-19 infected or where such an infection has been strongly suspected.
|
IEC Statement on COVID 19
IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information.
|
|
|
|
|
|
Page 1 of 2 |
